Applied Clinical Trials-05-01-2024

Click the title above for a link to open the Applied Clinical Trials May 2024 issue in an interactive PDF format.

While recent improvement in clinical trial enrollment levels in cancer may seem modest, there are notable advancements moving the needle in expanding the pool of potential participants, as our May issue explores.

Promising scientific advances are pacing oncology drug development.

Sharing an entertaining dive into the origins, milestones, and future of behavioral economics—where lessons can be applied to clinical practice.

The potential of PBPK modeling in answering key questions around these drugs.

A forum of prominent industry stakeholders highlights the challenges for patients in navigating the multiple legal, regulatory, and ethical barriers to cross-border participation.

How innovative trial designs and advanced imaging modalities can address the challenges of early drug development to optimize outcomes for patients with solid tumors.

Felix addresses a variety of topics around artificial intelligence including challenges, streamlining data management, and human intervention.

The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.